syrosingopine has been researched along with metformin in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Benjamin, D; Betz, C; Colombi, M; El-Shemerly, MY; Hall, MN; Hindupur, SK; Lane, HA; Lu, M; Moes, S; Moroni, C; Quagliata, L; Sharpe, T; Terracciano, L; Wodnar-Filipowicz, A | 1 |
| Benjamin, D; Colombi, M; El-Shemerly, MY; Hall, MN; Hindupur, SK; Lane, HA; Maira, SM; Moroni, C; Pohlmann, J; Robay, D | 1 |
| Ates, G; De Bruyne, E; De Veirman, K; Faict, S; Fan, R; Maes, A; Massie, A; Menu, E; Oudaert, I; Satilmis, H; Van der Vreken, A; Vanderkerken, K; Vlummens, P | 1 |
3 other study(ies) available for syrosingopine and metformin
| Article | Year |
|---|---|
Syrosingopine sensitizes cancer cells to killing by metformin.
Topics: Animals; Cell Line, Tumor; Drug Synergism; Glycolysis; Humans; Metformin; Mice; Mice, Knockout; Phenformin; Phosphopyruvate Hydratase; Reserpine | 2016 |
Dual Inhibition of the Lactate Transporters MCT1 and MCT4 Is Synthetic Lethal with Metformin due to NAD+ Depletion in Cancer Cells.
Topics: Acids; Animals; Cell Line, Tumor; Energy Metabolism; Humans; Intracellular Space; Lactic Acid; Male; Metformin; Mice, Inbred C57BL; Monocarboxylic Acid Transporters; Muscle Proteins; NAD; Neoplasms; Reserpine; Symporters; Synthetic Lethal Mutations | 2018 |
Metformin confers sensitisation to syrosingopine in multiple myeloma cells by metabolic blockage and inhibition of protein synthesis.
Topics: Antineoplastic Agents; Cell Line, Tumor; Humans; Lactic Acid; Metformin; Monocarboxylic Acid Transporters; Multiple Myeloma | 2023 |